



LEMBAGA PEMULIHAN DAN PENGELOLAAN LINGKUNGAN INDONESIA

Head Office: Jl. Cempaka Putih Tengah III No. 6A Jakarta pusat

S.197/INN/LP2LI/V/2020

To whom it my concern

Subject: Certificate of Authorization to Develop Covid 19 Vaccine with a Vaccine Production Facility/Facilities, with the leadership team of Experts and Scientists, identified and presented


Innovation specialists Consortium, of leadership experts & scientists, from Egypt and Iraq, with an Investments consortium from Thailand, and Multifunctional leadership Team from Kuwait and other countries to start first coronavirus vaccine trial under Indonesian official blessing.

With more than 2.5 million people now infected worldwide in the COVID-19 pandemic, Indonesia has authorized the preclinical, clinical trial, and the mass production, to making coronavirus covid 19 vaccine. The first human tests will begin before the end of July 2020.

Closeup of a needle with a drop of vaccine at the end, Lembaga Pengelolaan dan Pemulihan Lingkungan Indonesia (LP2LI), Hereby, this certificate of approval to DEVELOP the COVID 19 VACCINE WITH A VACCINE PRODUCTION FACILITY/FACILITIES technology transfer. the Indonesian Environmental Management and Recovery Institute, represented by its executive Director (DIREKTUR EKSEKUTIF), Mr. TROY EVELON POMALINGO, has declared the time of first clinical trials of a coronavirus vaccine, Jointly with the regulatory authority which helps develop and authorizes vaccines in Indonesia, has given the go-ahead for the Preclinical and Clinical trials of a vaccine against the SARS-CoV-2 virus. within the consortium territories.

It was developed by cancer researcher and immunologist Dr. Sherif Salah and his team at pharmaceutical company DermaCure-KMWSH and is based on their prior research into cancer immunology. Salah previously taught at the University of Cairo before becoming the CEO of DermaCure, the subsidiary of KMWSH.

Dr. Salah explained that innocuous genetic information of the SARS-CoV-2 virus is transferred into human cells with the help of lipid nanoparticles, a non-viral gene delivery system. The cells then transform this genetic information into a protein, which should stimulate the body's immune reaction to secrete an uncontrolled cytokines storm to the novel coronavirus. Aside from which is now in the stage 1 testing phase, DermaCure, jointly with KMWSH www.kmwsh.nl are working to developing a novel vaccine comprising viral Target Antigens and neutralizing nonspecific antibody (immune complex). This will be the first vaccine trail in the Middle East used viral Target Antigens and neutralizing nonspecific antibody.



The first medical tests will involve 200 healthy volunteers between the ages of 18 and 55. The aim is to determine the immune response and whether the vaccine causes any unwanted side effects. "Trials of vaccine candidates in humans are an important milestone on the road to safe and efficacious vaccines against COVID-19 for the population in Indonesia and internationally," The Senior Leadership Team of Experts and Scientists, said. Salah said testing would be completed by September, after that stage is complete.

Inside **DermaCure-KMWSH**, R&D divisions, in the field of biotechnology and bio-security - moving very quickly trying to create a vaccine for the covid-19 virus, here at KMWSH our R&D team was alerted to what happened in 2012 due to the MERS epidemic that occurred in the KSA, and since that time we started to Developing a vaccine therapeutic treatment. in addition, and based on our previously research, conducted by us on HIV to analyze how it works, as this vaccine was built on a new method that makes it able to deal with all mutant and encapsulated viruses.

This makes scientists believe it is a sign that the body is doing a positive immune reaction but in reality it is a sign that the coupling reaction between the virus and antibodies has been synthesized making an intrinsic circulating immune complex that gives the virus the ability to idle for a period and activity several times more which causes us to believe it disappears. The consortium plan to complete phase I clinical trials as soon as possible and, if successful and subject to regulatory considerations, aim to complete the development required this year.

| Vaccine | Company | Platform | Stage | Start Date | Description | Location |
|--------------|---|-------------|--------------|--|--|--|
| CRCx vaccine | Derma Cure – KMWSH LTD. and Collaborators | Inactivated | Phase II-III | 27.05.2020 based or Researches & Development Since 2012 - 2015 | This is will be the first vaccine in the middle East, Asia, and Africa it will test three candidate's vaccine formulations | Inventors from Egypt & Iraq with collaboration from Indonesia, Thailand, Kuwait, Turkey & Jordan |

Indonesian Government Relationship & covid 19 vaccine project coordinator

1. Lembaga Pengelolaan dan Pemulihan Lingkungan Indonesia (LP2LI), The Indonesian Environmental Management and Recovery Institute, Represented by its executive Director (DIREKTUR EKSEKUTIF), Mr. TROY EVELON POMALINGO

Head office: JL. CEMPAKA PUTIH TENGAH III NO. 6A JAKARTAPUSAT

Direct Phone: +62 813 1694 7198/ +62 877 8445 3789

DERMA-CURE KMWSH, Senior Leadership Team of Experts and Scientists:

2. DERMA-CURE FOR PHARMACEUTICAL INDUSTRIES, (EGYPTIAN COMPANY), Represented by its executive Director, Mr. SHERIF SALAH ABDELAZIZ HESEN (Egyptian Citizen - Inventor) holder of passport No. A23407593, (Bio-inventor and/or Inventor), whose address for courier:

Address: Villa 165, 5th Compound, El-banafseg 3, New Cairo, Egypt

Mail: ceo@dermacure-egypt.com

Direct Phone: +201005218981

3. KMWSH ENDÜSTRİYEL PROJE SANAYİ VE TİCARET LİMİTED ŞİRKETİ. Represented by its executive Director, Mr. MUAYAD S. DAWOOD AL-SAMARAE (Inventor) Holds Iraqi passport No. A17420623 and Jordanian passport No. P756917, whose address for courier:

Address: YENİGÜN MAH. 1047 SK. NO: 7 İÇ KAPI NO: 11 MURATPAŞA/ ANTALYA

Contact Information: covid19@kmwshglobal.com / coronavirus@kmwshglobal.com

Direct Phone: +905070800865

IMSMART, Investments Consortium:

4. PT. IMSMART IMT, NPWP: 93.222.486.8-015.000, in INDONESIA. Represented by its executive Director, MISS MANDALA SOOTTAPINTU, holder of Thailand Passport No: AA8053260, whose address for courier:

Address: Ascom Jl. K.H. Abdullah Syafe'i No. 23A, Kebun Baru, Tebet, Jakarta Selatan, DKI Jakarta, Indonesia

Email: ceo@imsmart-indonesia.com

Direct Phone: +66 98 849 4601

Office Phone: +62 83796630-32

IMSMART & DERMA-CURE KMWSH, Multifunctional leadership Team:

5. PT. IMSMART IMT, NPWP: 93.222.486.8-015.000, in INDONESIA. Represented by its executive Director, Mr. THANAKRIT ATSWALONGKORN (Business Development Expert), holder of Thailand Passport No: AA7558374, whose address for courier:

Address: Ascom Jl. K.H. Abdullah Syafe'i No. 23A, Kebun Baru, Tebet, Jakarta Selatan, DKI Jakarta, Indonesia

Email: thanakrit@imsmart-indonesia.com

Direct Phone: +666-2636-5391

Office Phone: +62 83796630-32

6. KMWSH ENDÜSTRİYEL PROJE SANAYİ VE TİCARET LİMİTED ŞİRKETİ.
Represented by its executive Director, Mr. WALID ALROOMI (Business
Development Expert) Holds Kuwaiti passport No. P05454382, whose address
for courier:

Address: YENİGÜN MAH., 1047 SK. NO: 7 İÇ KAPI NO: 11 MURATPAŞA/ ANTALYA


Contact Information: walid@kmwshglobal.com

Direct Phone: +965 50626268

Note: This certificate of approvals issued based on DERMA-CURE KMWSH
consortium [references](#) and the copyrighted Attachments:
8561260420S005_KMWSHBiotechBiosecurityandBio-AiResearch-
DevelopmentDepartmentII-3BR2D – www.kmwsh.nl

Jakarta, May 27 2020


Very Truly Yours,
INDONESIAN INSTITUTE FOR ENVIROMENTAL
MANAGEMENT & RESTORATION



TROY EVELON POMALINGO
Executive Director

Waarmerking Number : *288/purwakarta/2020*

This document has been registered in the registered
book for that purpose by me, **AULIA ABDI**, Master of Law,
Magister of Public Notary, Notary in Purwakarta.
Purwakarta *27-05-2020*



A. AULIA ABDI, S.H., M.Kn.



استلمت مبلغ (٢٠٠) \$ بموجب صندوق رقم
 وصل 137 المرقم (١٠٨٤)
 2 SEP 2020
 عمر محمد جمعة

CONSULAR SECTION KUWAIT AUTHENTICATION

القسم القنصلي الكويت التصديقات

العدد: 396
 التاريخ: 2-9-2020
 الخاريجة الكويتية

We approve the validity of the seal and the signature
 The Dept Not Responsible for it's contents

EMBA S S I OF THE REPUBLIC OF IRAQ

عبد الوهاب الصوافي

KEMENTERIAN HUKUM DAN HAM RI
 DIREKTORAT JENDERAL ADMINISTRASI HUKUM JAKARTA, 28 Juli 2020
 Nomor : 015435/0604/2020
 LEGALISASI TANDA TANGAN



DIREKTUR PERDATA
 Santun Maspari Siregar, S.H., M.H.
 19670505-399183-3-003
 2. Pemohon sudah mengetahui syarat legalisasi negara tujuan dan bertanggung jawab penuh terhadap pemenuhan syarat tersebut

NOTARIS
 Aulia Abdi, S.H., M.Kn
 Notaris Kabupaten Purwakarta

KEMENTERIAN LUAR NEGERI RI
 MINISTRY OF FOREIGN AFFAIRS REPUBLIC OF INDONESIA

No : 2010010035296

lihat untuk pengesahan tanda tangan :
 seen for legalization the signature of
 Santun Maspari Siregar
 Direktur Perdata Kementerian Hukum & HAM

Jakarta, 28 Juli 2020
 Tanda tangan :
 Signature

Zaenal Abidin
 Deputy Director for Legalization

Kementerian Luar Negeri RI tidak bertanggung jawab atas isi dokumen
 The Ministry is not responsible for the content of the document

015435/0604/2020
 JAKARTA
 0113236

No. 4 17 /Kons/KWT/ VIII/ 2020

The Signature of **MR. ZAENAL ABIDIN**
DEPUTY DIRECTOR FOR LEGALIZATION
 Consular Department of Ministry of Foreign Affairs
 of Republic of Indonesia, seen and acknowledge as
 authentic.

The Embassy is not responsible to the content.
 Kuwait, 27 AUG 2020
 Ambassador

Ahmad Fachruddin Hasan



First Secretary
 Certified for the legalization
 of the seal & signature of the
 Ministry of Foreign Affairs
 for the State of Kuwait on
 this - 7 SEP 2020
 at the U.S. Embassy Kuwait

Nikhil Lakhnarpal
 Vice Consul of the
 United States of America

01 SEP 2020

تصادق على صحة توقيع وختم
 على الوثيقة دون أدنى مسئولية فيما يخص
 محتوياتها

تسليم دفع
 5.0 دينار
 31/08/2020 09:03:01
 2778300241761246

وزارة الخارجية الكويتية - شؤون القنصلي
 تصادق على صحة توقيع وختم
 31 AUG 2020



دون أدنى مسؤولية فيما يخص محتويات هذه الوثيقة

EMBA S S I OF THE REPUBLIC OF KUWAIT

Özel No: 2021
 Sıra No: 27220799
 Tarife: 511139
 Harç: 6 KD
 Tarih: 31.08.2020

Muhsyin ISPIR
 İkinci Katip
 Second Secretary